Abstract:Metastatic prostate cancer (PCa) frequently occurs in the bone and can remain inactive for extended periods after primary tumor treatment. Understanding the intricate molecular mechanisms that govern this phenomenon could open the door to novel therapies, potentially reducing mortality rates. To address this, we developed a novel protocol to induce cellular dormancy in PCa cell lines (RM1, 22Rv1, LAPC4) in vitro. We noted that dormant cells exhibited distinctive clustering and could be reactivated when exposed to serum even after 21 days of stasis. The dormancy program was validated by multiple assays including cell cycle analysis, membrane dye retention, and Edu+ incorporation. RNASeq analysis showed significant transcriptional changes during dormancy induction, with 8 genes commonly upregulated across multiple human and mouse PCa cell lines, of which the transcription factor, PRDM16. We focused on PRDM16 since, 1) it is a known regulator of hematopoietic stem cell quiescence, 2) our emerging data points to bone morphogenetic protein-7 (BMP7), a well-known exogenous mediator of dormancy as an inducer of PRDM16 expression and 3) clinically, PRDM16 is suppressed in primary PCa and active metastases. First, we validated the upregulation of PRDM16 during dormancy in vitro. Silencing PRDM16 led to impaired dormancy phenotype and cell death, while its overexpression significantly mitigated proliferation rates and promoted survival. In vivo, we employed an intra-iliac immunocompetent model (RM1 & C57BL6J) and demonstrated that overexpressing PRDM16 in active RM1 cells resulted in significant reduction of metastasis formation and Ki67 expression concurrent with extended survival when injected in vivo compared to control cells. Prostate cancer cells with PRDM16 over-expression were detected in bone sections as solitary or small clusters (<20 cells) demonstrating an inverse relationship between PRDM16 expression and metastatic outbreak. In defining the targets via which PRDM16 controls dormancy entry, we focused on RAR related orphan receptor C (RORC) based on bioinformatic analysis and publicly available PRDM16 ChIP-Seq. Our data demonstrate that pharmacological inhibition of RORC using GSK805 promoted the apoptosis of dormant PCa cells specifically when compared to their actively growing counterparts. In conclusion, our studies have revealed the critical role of PRDM16 in promoting PCa cell dormancy, in part via upregulating RORC. Translationally, clinically approved RORC inhibitors for non-cancerous conditions (psoriasis) have been developed. We expect, based on our results, that these inhibitors could be repurposed for the eradication of dormant PCa cells in patients with advanced disease. Citation Format: Mostafa M. Nasr, Tao Li, Ryan T. Bishop, Jeremy S. Frieling, Conor C. Lynch. PRDM16 is an intrinsic regulator of dormancy in bone disseminated prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5539.

Data from Functional Coupling of P38-Induced Up-regulation of BiP and Activation of RNA-Dependent Protein Kinase–Like Endoplasmic Reticulum Kinase to Drug Resistance of Dormant Carcinoma Cells

Autophagy Inhibition Contributes to Apoptosis of PLK4 Downregulation-induced Dormant Cells in Colorectal Cancer

Activation of Anaphase-Promoting Complex by P53 Induces A State of Dormancy in Cancer Cells Against Chemotherapeutic Stress

Pharmacological Inhibition Of P38 Mapk By Sb203580 Increases Resistance To Carboplatin In A2780cp Cells And Promotes Growth In Primary Ovarian Cancer Cells

Targeting UPR branches, a potential strategy for enhancing efficacy of cancer chemotherapy

Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells

Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy

TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR

The role of cancer cell bioenergetics in dormancy and drug resistance

Dormancy-inducing 3D-engineered matrix uncovers mechanosensitive and drug protective FHL2-p21 signaling axis

Role of P38 in endoplasmic reticulum stress-induced chemoresistance to cisplatin in gastric cancer cells

Endoplasmic Reticulum Stress Promotes Autophagy and Apoptosis and Reduces Chemotherapy Resistance in Mutant p53 Lung Cancer Cells

A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells

Tumor Dormancy Within the Lymphovascular Embolus Is Regulated by Multiple Metabolism-signaling Pathways

Blockade of the LRP16-PKR-NF-κB Signaling Axis Sensitizes Colorectal Carcinoma Cells to DNA-damaging Cytotoxic Therapy.

Abstract 2449: P38β Promotes Cancer Stemness and Chemoresistance in Hepatocellular Carcinoma

Mitophagy-Mediated Tumor Dormancy Protects Cancer Cells from Chemotherapy

Inhibition of P38 MAPK Diminishes Doxorubicin-Induced Drug Resistance Associated with P-glycoprotein in Human Leukemia K562 Cells

Abstract 5539: PRDM16 is an intrinsic regulator of dormancy in bone disseminated prostate cancer cells

Insulin Resistance Contributes to Multidrug Resistance in HepG2 Cells Via Activation of the PERK Signaling Pathway and Upregulation of Bcl-2 and P-gp.

PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer